SIGA Technologies (SIGA) has been awarded a multi-year contract from the United States Department of Defense to support work necessary to gain a potential label expansion for TPOXX (tecovirimat) that would include Post-Exposure Prophylaxis (PEP) of smallpox.
The contract is valued at up to $19.5M, with an initial award of $12.4M.
The initial funding will support manufacturing material for clinical trials, initial preparation for a human clinical safety study, and assembling regulatory filings.
TPOXX, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug is used for the treatment of human smallpox disease caused by variola virus.
Subscribe for full text news in your inbox